Ticker Details
Gilead Sciences, Inc. Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
IPO Date:	January 3, 1994
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$167.41B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.88 | 1.31%
Avg Daily Range (30 D):	$2.06 | 1.62%
Avg Daily Range (90 D):	$1.79 | 1.34%

Institutional Daily Volume
Avg Daily Volume:	8.98M
Avg Daily Volume (30 D):	5.75M
Avg Daily Volume (90 D):	4.6M

Trade Size
Avg Trade Size (Sh.):	166
Avg Trade Size (Sh.) (30 D):	57
Avg Trade Size (Sh.) (90 D):	56

Institutional Trades
Total Institutional Trades:	124,697
Avg Institutional Trade:	$5.63M
Avg Institutional Trade (30 D):	$23.34M
Avg Institutional Trade (90 D):	$22.16M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	21

Market Closing Trades
Avg Closing Trade:	$60.55M
Avg Closing Trade (30 D):	$285.64M
Avg Closing Trade (90 D):	$223.96M
Avg Closing Volume:	868.35K

News

Jul 8, 2026 @ 11:28 AM BBH vs. XPH: Which Healthcare ETF Is Better for Be... Source: Sarah Sidlow

Jul 7, 2026 @ 2:00 PM BBG Advanced Therapies Launches Mobile Leukapheres... Source: Not Specified

Jun 9, 2026 @ 5:44 PM Gilead And Merck End Trodelvy-Keytruda Lung Cancer... Source: Vandana Singh

Jun 2, 2026 @ 5:47 PM Gilead Advances Liver Disease Ambitions With Encou... Source: Vandana Singh

May 30, 2026 @ 12:21 AM Tango Therapeutics Stock Is Up 840%, and This Fund... Source: Jonathan Ponciano

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$7.42	$1.63	$1.76
Diluted EPS	$7.34	$1.61	$1.74
Revenue	$29.74B	$6.96B	$7.93B
Gross Profit	$23.6B	$5.52B	$6.3B
Net Income / Loss	$9.22B	$2.02B	$2.18B
Operating Income / Loss	$10.37B	$2.59B	$1.98B
Cost of Revenue	$6.14B	$1.45B	$1.62B
Net Cash Flow	$-298M	$64M	$234M
PE Ratio

Splits
Jan 28, 2013	2:1
Jun 25, 2007	2:1
Sep 07, 2004	2:1
Mar 08, 2002	2:1
Feb 22, 2001	2:1